Albertsons and CarMax fall following quarterly earnings Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- Aeglea BioTherapeutics (AGLE) up 18% after announcing its PEACE Phase 3 study achieved its primary endpoint
- Biodesix (BDSX) up 50% after announcing director Matthew Strobeck purchased 558,659 shares of company stock at $1.79 per share on April 7 for a total transaction amount of $1,000,000
- Cyclacel Pharmaceuticals (CYCC) up 12% after announcing a publication in the journal Leukemia titled "Cyclin-dependent kinase inhibitor fadraciclib depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells"
- BioCardia (BCDA) up 24% after announcing that the FDA has approved the company's investigational new drug application for BCDA-04, a proprietary allogeneic mesenchymal cell population that is Neurokinin-1 receptor positive
UP AFTER EARNINGS -
DOWN AFTER EARNINGS -
- Albertsons (ACI) down 3%
- CarMax (KMX) down 4%
- Airspan Networks (MIMO) down 4%
LOWER -
- Myovant Sciences (MYOV) down 21% after the company and Pfizer (PFE) announced the FDA identified deficiencies in the supplemental new drug application, or sNDA, for Myfembree for the management of moderate to severe pain associated with endometriosis
- HP Enterprise (HPE) down 3% after Morgan Stanley analyst Meta Marshall downgraded the stock to Underweight from Equal Weight
- Cisco (CSCO) down 2% after Citi analyst Jim Suva downgraded shares to Sell from Neutral
Symbols:
AGLE BDSX CYCC BCDA OGI ACI KMX MIMO MYOV HPE CSCO PFE Keywords: Fly Intel, Wall Street, Top Stories, Stocks